Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy

References

• Early Breast Cancer Trialists’ Collaborative Group.Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687–717.
   PubMed Web of Science ®Google Scholar
• Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181–7.
   PubMed Web of Science ®Google Scholar
• Warwick J, Tabar L, Vitak B, Duffy SW. Time-dependent effects on survival in breast carcinoma: Results of 20 years of follow-up from the Swedish Two-County Study. Cancer 2004;100:1331–6.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133–44.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Breast Cancer, Version 2. 2011. Available from: http://www.nccn.com [cited 2012 January 17].
   Google Scholar
• Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319–29.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes – dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736–47.
   PubMed Web of Science ®Google Scholar
• Norsk bryst cancer gruppe. Available from: http://www.nbcg.no. [cited 2012 January 17].
   Google Scholar
• Grogan M, Tabar L, Chua B, Chen HH, Boyages J. Estimating the benefits of adjuvant systemic therapy for women with early breast cancer. Br J Surg 2001;88:1513–8.
   PubMed Web of Science ®Google Scholar
• Filho OM, Ignatiadis M, Sotiriou C. Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis. Crit Rev Oncol Hematol 2011;77:20–9.
   PubMedGoogle Scholar
• Oakman C, Bessi S, Zafarana E, Galardi F, Biganzoli L, Di LA. Recent advances in systemic therapy: New diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res 2009;11:205.
   PubMedGoogle Scholar
• Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, . Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160–7.
   PubMed Web of Science ®Google Scholar
• Perou CM, Borresen-Dale AL. Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol 2011;3.
   PubMed Web of Science ®Google Scholar
• Slodkowska EA, Ross JS. MammaPrint 70-gene signature: Another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn 2009;9:417–22.
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790–800.
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, . A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347: 1999–2009.
   PubMed Web of Science ®Google Scholar
• Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, . Meta-analysis of gene expression profiles in breast cancer: Toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008;10:R65.
   PubMed Web of Science ®Google Scholar
• Naume B, Borgen E, Kvalheim G, Karesen R, Qvist H, Sauer T, . Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: Comparison with preoperative clinical parameters and primary tumor characteristics. Clin Cancer Res 2001;7:4122–9.
   PubMed Web of Science ®Google Scholar
• Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland JM, Qvist H, . Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 2003;21:3469–78.
   PubMed Web of Science ®Google Scholar
• Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991;19:403–10.
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067–72.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Nielsen TO, A’hern R, Bartlett J, Coombes RC, Cuzick J, . Assessment of Ki67 in breast cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011;103:1656–64.
   PubMed Web of Science ®Google Scholar
• Jung SY, Han W, Lee JW, Ko E, Kim E, Yu JH, . Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol 2009;16:1112–21.
   PubMed Web of Science ®Google Scholar
• Chin SF, Daigo Y, Huang HE, Iyer NG, Callagy G, Kranjac T, . A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples. Mol Pathol 2003;56:275–9.
   PubMedGoogle Scholar
• Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18–43.
   PubMed Web of Science ®Google Scholar
• Azim HA, Jr., de AE, Colozza M, Bines J, Piccart MJ. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol 2011;22:1939–47.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Ginsburg OM, Wijeratne TD, Howell A, Evans G, Sestak I, . Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review. Cancer Treat Rev 2012;38:318–28.
   PubMed Web of Science ®Google Scholar
• Zambetti M, Moliterni A, Materazzo C, Stefanelli M, Cipriani S, Valagussa P, . Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 2001;19:37–43.
   PubMed Web of Science ®Google Scholar
• Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, . Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 2011;378: 771–84.
   PubMed Web of Science ®Google Scholar
• Grasic-Kuhar C, Bracko M, Zakotnik B. Risk factors for late relapse and death in patients with early breast cancer. Neoplasma 2008;55:416–20.
   PubMed Web of Science ®Google Scholar
• Eden P, Ritz C, Rose C, Ferno M, Peterson C.“Good Old” clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 2004;40:1837–41.
   PubMed Web of Science ®Google Scholar
• Geradts J, Bean SM, Bentley RC, Barry WT. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest 2010;28:969–77.
   PubMed Web of Science ®Google Scholar
• Lee AH, Ellis IO. The Nottingham prognostic index for invasive carcinoma of the breast. Pathol Oncol Res 2008;14:113–5.
   PubMed Web of Science ®Google Scholar
• Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, . Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010;7:e1000279.
   PubMed Web of Science ®Google Scholar
• Christiansen P, Bjerre K, Ejlertsen B, Jensen MB, Rasmussen BB, Laenkholm AV, . Mortality rates among early-stage hormone receptor-positive breast cancer patients: A population-based cohort study in Denmark. J Natl Cancer Inst 2011;103:1363–72.
   PubMedGoogle Scholar
• Strand C, Ahlin C, Bendahl PO, Fjallskog ML, Hedenfalk I, Malmstrom P, . Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer. Breast Cancer Res Treat 2012;131:33–40.
   PubMed Web of Science ®Google Scholar
• Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, . Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101: 736–50.
   PubMed Web of Science ®Google Scholar
• de Azambuja E, Cardoso F, de CG, Jr., Colozza M, Mano MS, Durbecq V, . Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007;96:1504–13.
   PubMed Web of Science ®Google Scholar
• van Diest PJ, van der WE, Baak JP. Prognostic value of proliferation in invasive breast cancer: A review. J Clin Pathol 2004;57:675–81.
   PubMed Web of Science ®Google Scholar
• Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: Prognostic and predictive potential. Lancet Oncol 2010;11:174–83.
   PubMed Web of Science ®Google Scholar
• Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, . Ki-67 expression in breast carcinoma: Its association with grading systems, clinical parameters, and other prognostic factors – a surrogate marker?Cancer 2003;97:1321–31.
   PubMed Web of Science ®Google Scholar
• Luporsi E, Andre F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, . Ki-67: Level of evidence and methodological considerations for its role in the clinical management of breast cancer: Analytical and critical review. Breast Cancer Res Treat 2012;132:895–915.
   PubMed Web of Science ®Google Scholar
• Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008;17:323–34.
   PubMed Web of Science ®Google Scholar
• Ruiz C, Seibt S, Al KK, Siraj AK, Mirlacher M, Schraml P, . Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer 2006;118:2190–4.
   PubMed Web of Science ®Google Scholar
• Mohammed RA, Ellis IO, Mahmmod AM, Hawkes EC, Green AR, Rakha EA, . Lymphatic and blood vessels in basal and triple-negative breast cancers: Characteristics and prognostic significance. Mod Pathol 2011;24:774–85.
   PubMed Web of Science ®Google Scholar
• Mohammed RA, Martin SG, Mahmmod AM, Macmillan RD, Green AR, Paish EC, . Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma: Findings from a large case series with long-term follow-up. J Pathol 2011;223:358–65.
   PubMed Web of Science ®Google Scholar
• Sabatier R, Jacquemier J, Bertucci F, Esterni B, Finetti P, Azario F, . Peritumoural vascular invasion: A major determinant of triple-negative breast cancer outcome. Eur J Cancer 2011;47:1537–45.
   PubMed Web of Science ®Google Scholar
• Lee AH, Pinder SE, Macmillan RD, Mitchell M, Ellis IO, Elston CW, . Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur J Cancer 2006;42:357–62.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569–83.
   PubMed Web of Science ®Google Scholar
• Sloane JP, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, . Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. European Commission Working Group on Breast Screening Pathology. Virchows Arch 1999;434:3–10.
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, . Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262–72.
   PubMed Web of Science ®Google Scholar
• Paik S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 2007; 12:631–5.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, . Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 2011;29:4273–8.
   PubMed Web of Science ®Google Scholar
• Auerbach J, Kim M, Fineberg S. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?Arch Pathol Lab Med 2010;134:1697–701.
   PubMed Web of Science ®Google Scholar
• Flanagan MB, Dabbs DJ, Brufsky AM, Beriwal S, Bhargava R. Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol 2008;21:1255–61.
   PubMed Web of Science ®Google Scholar
• Kim C, Paik S. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol 2010;7:340–7.
   PubMed Web of Science ®Google Scholar
• Mehta R, Jain RK, Badve S. Personalized medicine: The road ahead. Clin Breast Cancer 2011;11:20–6.
   PubMed Web of Science ®Google Scholar
• Parisi F, Gonzalez AM, Nadler Y, Camp RL, Rimm DL, Kluger HM, . Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. Breast Cancer Res 2010;12:R66.
   PubMed Web of Science ®Google Scholar
• Zhao X, Rodland EA, Sorlie T, Naume B, Langerod A, Frigessi A, . Combining gene signatures improves prediction of breast cancer survival. PLoS One 2011;6: e17845.
   Google Scholar